Rullas, JoaquinDhar, NeerajMckinney, John D.Garcia-Perez, AdolfoLelievre, JoelDiacon, Andreas H.Hugonnet, Jean-EmmanuelArthur, MichelAngulo-Barturen, InigoBarros-Aguirre, DavidBallell, Lluis2015-12-022015-12-022015-12-02201510.1128/Aac.01063-15https://infoscience.epfl.ch/handle/20.500.14299/120930WOS:000362952000080We report here a dehydropeptidase-deficient murine model of tuberculosis (TB) infection that is able to partially uncover the efficacy of marketed broad-spectrum beta-lactam antibiotics alone and in combination. Reductions of up to 2 log CFU in the lungs of TB-infected mice after 8 days of treatment compared to untreated controls were obtained at blood drug concentrations and time above the MIC (T->MIC) below clinically achievable levels in humans. These findings provide evidence supporting the potential of beta-lactams as safe and mycobactericidal components of new combination regimens against TB with or without resistance to currently used drugs.text::journal::journal article::research article